Gsk (GSK) Income from Continuing Operations (2009 - 2026)
Gsk (GSK) posted Income from Continuing Operations of $2.91 billion for the quarter ended Sep 30, 2026, down 22.1% from $3.74 billion a year earlier.
Powered by 
Analysis
Gsk (GSK) Income from Continuing Operations (2009 - 2026) Analysis & Trends
For the trailing twelve months through Sep 30, 2026, Income from Continuing Operations at Gsk was $16.92 billion, up 65.8% year-over-year; for the year ended Dec 31, 2025, it was $8.29 billion, up 119.8% from the prior year.
- Annual Income from Continuing Operations shows a five-year compound annual growth rate of 4.8% (years ended Dec 2020 to Dec 2025).
- In prior years, Gsk's Income from Continuing Operations was $3.77 billion in the year ended Dec 31, 2024 (-42.9%), $6.6 billion in the year ended Dec 31, 2023 (+8.4%), $6.09 billion in the year ended Dec 31, 2022 (+25.9%) and $4.84 billion in the year ended Dec 31, 2021 (-26.2%).
- Quarterly Income from Continuing Operations has run from a low of $81.86 million in the quarter ended Sep 30, 2024 to a high of $11.32 billion in the quarter ended Dec 31, 2025 over five years.
- On a year-over-year basis, Income from Continuing Operations increased in four of the last seven quarters, with growth averaging 89.4%.
- The strongest year-over-year quarter for Income from Continuing Operations in the past five years was the quarter ended Dec 31, 2022, with growth of 811.2%; the weakest was the quarter ended Sep 30, 2024, with a decline of 95.6%.
- According to Business Quant data, Income from Continuing Operations for the three prior quarters was $207.96 million (quarter ended Jun 30, 2026), $2.48 billion (quarter ended Mar 31, 2026) and $11.32 billion (quarter ended Dec 31, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,267.78 Bn | 1,241.40 Bn | 20.46 Bn | 6.45 Bn |
| 2 | Johnson & Johnson | 659.28 Bn | 579.14 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 514.51 Bn | 482.52 Bn | 13.12 Bn | 4.22 Bn |
| 4 | Merck | 367.42 Bn | 321.80 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 319.10 Bn | 292.34 Bn | - | - |
| 6 | Astrazeneca | 293.31 Bn | 267.20 Bn | 13.26 Bn | 4.80 Bn |
| 7 | Amgen | 258.69 Bn | 214.09 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 216.51 Bn | 191.61 Bn | 6.73 Bn | 2.43 Bn |
| 9 | Pfizer | 174.99 Bn | 121.63 Bn | 10.94 Bn | -246.00 Mn |
| 10 | Gsk | 103.65 Bn | 86.50 Bn | 8.73 Bn | 2.91 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 2.91 Bn |
| Jun 30, 2026 | 207.96 Mn |
| Mar 31, 2026 | 2.48 Bn |
| Dec 31, 2025 | 11.32 Bn |
| Sep 30, 2025 | 3.74 Bn |
| Jun 30, 2025 | 2.84 Bn |
| Mar 31, 2025 | 2.23 Bn |
| Dec 31, 2024 | 1.40 Bn |
| Sep 30, 2024 | 81.86 Mn |
| Jun 30, 2024 | 2.13 Bn |
| Mar 31, 2024 | 1.37 Bn |
| Dec 31, 2023 | 493.98 Mn |
| Sep 30, 2023 | 1.94 Bn |
| Jun 30, 2023 | 2.18 Bn |
| Mar 31, 2023 | 1.98 Bn |
| Dec 31, 2022 | 1.91 Bn |
| Sep 30, 2022 | 2.86 Bn |
| Jun 30, 2022 | 939.45 Mn |
| Mar 31, 2022 | 2.38 Bn |
| Dec 31, 2021 | 687.49 Mn |
API Access
Gsk Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=GSK&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "GSK", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=GSK&period=max&api_key=YOUR_API_KEY");
const data = await res.json();